Baseline clinical characteristics of the GO-BEFORE and GO-FORWARD MRI substudy populations
| All MRI substudy patients | ||
|---|---|---|
| Characteristic | GO-BEFORE (methotrexate-naive) | GO-FORWARD (methotrexate inadequate response) |
| Patients randomly assigned to treatment, n | 318 | 240 |
| Women, n (%) | 257 (80.8%) | 200 (83.3%) |
| Median (IQR) | ||
| Age (years) | 50.0 (41.0–58.0) | 51.0 (43.0–58.0) |
| Disease duration (years) | 1.2 (0.6–3.7) | 6.3 (3.0–13.5) |
| Swollen joints (0–66) | 10.0 (7.0–16.0) | 10.0 (7.0–18.0) |
| Tender joints (0–68) | 23.5 (13.0–35.0) | 21.0 (11.0–31.0) |
| CRP (mg/dl) | 1.2 (0.5–2.7) | 0.8 (0.4–2.0) |
| ESR (mm/h) | 38.0 (22.0–58.0) | 36.0 (22.0–50.0) |
| DAS28 score (0–10) | 5.5 (4.8–6.3) | 5.3 (4.5–6.03) |
| Mean±SD | ||
| Median (IQR) | ||
| Total vdH-S score (0–448) | 20.5±38.15.5 (2.0–21.5) | 36.2±46.815.8 (2.5–50.8) |
| RAMRIS scores | ||
| Synovitis, wrist plus MCP (0–21)* | 9.5±5.09.5 (5.5–13.5) | 7.0±4.37.0 (3.5–9.5) |
| Bone oedema/osteitis (0–69) | 10.0±10.06.5 (2.5–15.5) | 6.9±9.12.0 (0.0–10.7) |
| Bone erosion (0–230) | 21.2±23.714.5 (10.0–22.5) | 24.4±28.113.9 (6.5–29.5) |
Data are presented for all treatment groups combined.
↵* Several sites did not have the capability to obtain postgadolinium images of both the wrist and the metacarpophalangeal joints; therefore, RAMRIS synovitis scores are summarised and assessed for the subgroups of patients with both determinations.
CRP, C-reactive protein; DAS28, 28-joint disease activity score calculated using CRP; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; RAMRIS, rheumatoid arthritis MRI scoring system; vdH-S, van der Heijde modified Sharp score.